NEW YORK (GenomeWeb) – Agilent Technologies announced that the US Food and Drug Administration has granted expanded approval to the firm's companion diagnostic for the Merck PD-L1 inhibitor Keytruda (pembrolizumab). The Dako PD-L1 IHC 22C3 pharmDx test can now be used to determine expression status and inform treatment in a broader range of metastatic non-small cell lung cancer (NSCLC) patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.